8-K: VSEE Health Regains Nasdaq Compliance with $13.2M Equity

VSEE Health, Inc. announced it has achieved pro forma compliance with Nasdaq's minimum stockholders' equity requirement, averting a potential delisting.

Summary

• VSEE Health, Inc. previously received a Nasdaq notification on September 2, 2025, for non-compliance with Listing Rule 5550(b)(1), requiring a minimum of $2,500,000 in stockholders' equity.
• As of December 31, 2024, the company reported a stockholders' deficit of $(18,488).
• Following an appeal and hearing on September 9, 2025, Nasdaq granted an exception, requiring compliance by December 1, 2025.
• The company believes it has demonstrated pro forma compliance through a series of transactions, including the exercise of warrants, conversion of convertible notes and preferred shares, and exchange of payables into common and preferred stock.
• A pro forma balance sheet as of December 31, 2025, reflects total stockholders' equity of $13,216,722, significantly exceeding the $2,500,000 minimum.

Sentiment

Score: 8

Explanation: The company successfully resolved a critical delisting threat by significantly improving its stockholders' equity position, which is a strong positive. However, the underlying financial performance that led to the initial deficit and the reliance on pro forma figures temper the sentiment slightly.

Positives

• Successfully achieved pro forma compliance with Nasdaq's Equity Rule 5550(b)(1), avoiding delisting.
• Stockholders' equity increased from a deficit of $(18,488) as of December 31, 2024, to a pro forma equity of $13,216,722 as of December 31, 2025.
• Conversion of outstanding convertible notes and payables into common and preferred stock strengthens the balance sheet by reducing liabilities.
• Continued listing on the Nasdaq Capital Market is secured, maintaining market access and liquidity.

Negatives

• The company was previously non-compliant with Nasdaq listing rules, indicating past financial challenges.
• Reported a significant stockholders' deficit of $(18,488) as of December 31, 2024.
• The compliance is based on a pro forma balance sheet, which assumes the completion of transactions and may not reflect immediate cash flow improvements.

Risks

• The underlying financial health that led to the initial stockholders' deficit may still pose long-term challenges if not addressed by sustainable profitability.
• Reliance on pro forma adjustments means the actual financial position could differ if the assumed transactions do not fully materialize or if other factors change.
• Future compliance with Nasdaq listing rules will require ongoing monitoring of financial performance and equity levels.

Future Outlook

The company has successfully demonstrated pro forma compliance with Nasdaq's Equity Rule, securing its continued listing on the Nasdaq Capital Market. This action resolves a significant immediate threat to its public trading status.

Management Comments

• The Company believes that it has demonstrated compliance with the Equity Rule on a pro forma basis following closing of the following the exercise of certain outstanding warrants, the conversion into common stock of multiple outstanding convertible notes and preferred shares, and the exchange of certain outstanding payables of the Company into common stock and preferred shares.

Industry Context

This filing highlights the ongoing scrutiny by Nasdaq on listed companies to maintain minimum financial standards, particularly stockholders' equity. For small-cap companies, meeting these requirements can be challenging, and non-compliance often leads to delisting threats. VSEE Health's actions to convert debt and payables to equity are a common strategy employed by companies to improve their balance sheet and meet listing requirements, especially in the healthcare technology sector where capital needs can be substantial.

Comparison to Industry Standards

• Nasdaq's $2.5 million minimum stockholders' equity rule is a standard benchmark for continued listing on its Capital Market, a requirement many smaller healthcare technology companies face.
• The conversion of debt and payables into equity is a common financial restructuring strategy employed by companies across various industries, particularly smaller-cap firms, to improve their balance sheet health and meet listing requirements. This approach is consistent with practices observed when companies need to rapidly bolster their equity position to avoid delisting, such as those seen in the biotechnology or emerging technology sectors where capital structures can be dynamic.

Related Party Transactions

• Due from related party: $284,614 (pro forma Dec 31, 2025)
• Due to related party: $51,900 (pro forma Dec 31, 2025)
• Quantum convertible note, related party at fair value: $3,248,000 (Dec 31, 2024, converted in pro forma)
• Loan payable, related party: $471,651 (pro forma Dec 31, 2025)

Stakeholder Impact

• Shareholders: Positive impact as the risk of delisting and potential loss of liquidity is averted, maintaining their investment's public market access.
• Creditors: Positive impact as convertible notes and payables have been converted to equity, reducing the company's debt burden and improving its balance sheet strength.
• Employees: Stability in the company's listing status can provide a sense of security regarding the company's future.

Next Steps

• Maintain compliance with Nasdaq's ongoing listing requirements.
• Focus on sustainable financial performance to ensure long-term equity stability.

Key Dates

Recommendation

The successful resolution of the Nasdaq delisting threat removes a significant overhang and uncertainty for VSEE Health, Inc. The substantial increase in stockholders' equity from a deficit to over $13 million demonstrates a strong commitment to financial stability and regulatory compliance. This mitigation of a major risk, coupled with the conversion of debt to equity, positions the company for renewed investor confidence and potential upside, making it a compelling "buy" for investors looking for a turnaround story with reduced immediate risk.

Keywords

VSEE Health, Nasdaq, Listing Compliance, Stockholders Equity, 8-K Filing, Delisting, Financial Compliance, Convertible Notes, Warrants, Balance Sheet